Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy

Published:2013-05-14 Issue:2 Volume:162 Page:229-239
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Harrison Claire N.¹,Mesa Ruben A.²,Kiladjian Jean-Jacques³,Al-Ali Haifa-Kathrin⁴,Gisslinger Heinz⁵,Knoops Laurent⁶,Squier Margaret⁷,Sirulnik Andres⁷,Mendelson Estella⁷,Zhou Xiaolei⁸,Copley-Merriman Catherine⁸,Hunter Deborah S.⁹,Levy Richard S.⁹,Cervantes Francisco¹⁰,Passamonti Francesco¹¹,Barbui Tiziano¹²,Barosi Giovanni¹³,Vannucchi Alessandro M.¹⁴

Affiliation:

1. Guy's and St. Thomas' NHS Foundation Trust; Guy's Hospital; London UK

2. Mayo Clinic; Scottsdale AZ USA

3. Hôpital Saint-Louis et Université Paris; Paris France

4. University of Leipzig; Leipzig Germany

5. Medical University of Vienna; Vienna Austria

6. Cliniques universitaires Saint-Luc and de Duve Institute; Université catholique de Louvain; Brussels Belgium

7. Novartis Pharmaceuticals Corporation; East Hanover NJ USA

8. RTI Health Solutions; Research Triangle Park NC USA

9. Incyte Corporation; Wilmington DE USA

10. Hospital Clínic; Institut d'Investigacions Biomèdiques August Pi i Sunyer; Barcelona Spain

11. Ospedale di Circolo e Fondazione Macchi; Varese Italy

12. A.O. Ospedali Riuniti di Bergamo; Bergamo Italy

13. Istituto di Ricovero e Cura a Carattere Scientifico; Policlinico San Matteo Foundation; Pavia Italy

14. University of Florence; Florence Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12375/fullpdf

Reference16 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;Journal of the National Cancer Institute,1993

2. Validation of the functional assessment of cancer therapy-lymphoma (FACT-LYM) in patients with relapsed/refractory mantle cell lymphoma;Carter;Blood,2008

3. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders;Cervantes;Leukemia,2008

4. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;New England Journal of Medicine,2012

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study;HemaSphere;2023-10-24

2. Еarly splenic response to ruxolitinib correlates with survival: a russian retrospective multicenter study in patients with myelofibrosis;Russian Journal for Personalized Medicine;2023-07-28

3. The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase;2023-05-12

4. Senescence and cancer — role and therapeutic opportunities;Nature Reviews Clinical Oncology;2022-08-31

5. Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study;European Journal of Haematology;2022-08-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3